Article Text

FRI0458 Assessment of Comorbidity in Psoriatic Disease: How Often Should Be Performed?
  1. L. Carmona1,
  2. J.C. Torre-Alonso2,
  3. M. Moreno3,
  4. E. Galíndez4,
  5. J. Babío5,
  6. P. Zarco6,
  7. L.F. Linares7,
  8. E. Collantes8,
  9. M. Fernández-Barrial9,
  10. J.C. Hermosa10,
  11. P. Coto11,
  12. C. Suárez12,
  13. R. Almodόvar6,
  14. J. Luelmo13,
  15. V. Cárcaba11,
  16. S. Castañeda14,
  17. T. Otόn1,
  18. R. Curbelo1,
  19. J. Gratacόs3
  1. 1Instituto de Salud Musculoesquelética, Madrid
  2. 2Department of Rheumatology, Hospital Virgen del Naranco, Oviedo
  3. 3Department of Rheumatology, Hospital Universitari Parc Taulí, Sabadell
  4. 4Department of Rheumatology, H. Universitario Basurto, Bilbao
  5. 5Department of Rheumatology, H. Cabueñes, Gijόn
  6. 6Department of Rheumatology, H. Fundaciόn Alcorcόn, Madrid
  7. 7Department of Rheumatology, H. Virgen de la Arrixaca, Murcia
  8. 8Department of Rheumatology, H. Reina Sofía, Cόrdoba
  9. 9C.S. de Sotondrio, Langreo
  10. 10C.S. de Getafe, Madrid
  11. 11Department of Dermatology, H.U. Central de Asturias, Oviedo
  12. 12Department of Internal Medicine, H. U. de la Princesa, IIS-Princesa, Madrid
  13. 13Department of Dermatology, Hospital Universitari Parc Taulí, Sabadell
  14. 14Department of Rheumatology, H.U. de la Princesa, IIS-Princesa, Madrid, Spain


Background Psoriatic disease (PsD) is associated with multiple comorbidities. When establishing management protocols, the periodicity for detection and evaluation of such comorbid conditions needs to be specified.

Objectives To establish guidelines for the follow-up of selected comorbidities in patients with PsD.

Methods An expert panel with specialists in Rheumatology, Internal Medicine, Dermatology and General Practitioners defined the comorbidities with higher impact on PsD based on the existing literature and their experience. The periodicity for detection and monitoring of comorbidities in the Rheumatology setting was established by consensus after iterations and systematic review.

Results The expert panel agreed to evaluate comorbidities as part of routine clinical practice at the time of diagnosis, upon changes in systemic treatment and at follow-up visits (evidence level 5, level of agreement 8.8). In any case, monitoring must be customized depending on the risk profile, morbidity, comorbidities and patient preferences. The following table shows the proposed periodicity for detection, assessment, and monitoring of the most important comorbidities in PsD.

Table 1

Conclusions This proposal for a periodic assessment of comorbidities in patients with PD allows systematic clinical monitoring of the patient by the Rheumatologist and Dermatologist, and can contribute to the early detection and management of these comorbidities

Acknowledgement The GECOAP project was funded by Merck Sharp & Dohme of Spain

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.